JP2001507713A - カルボン酸及びその誘導体及びそれらを含む薬剤組成物 - Google Patents
カルボン酸及びその誘導体及びそれらを含む薬剤組成物Info
- Publication number
- JP2001507713A JP2001507713A JP53069798A JP53069798A JP2001507713A JP 2001507713 A JP2001507713 A JP 2001507713A JP 53069798 A JP53069798 A JP 53069798A JP 53069798 A JP53069798 A JP 53069798A JP 2001507713 A JP2001507713 A JP 2001507713A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- compound
- active ingredient
- compound according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 150000001735 carboxylic acids Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 14
- 208000008589 Obesity Diseases 0.000 claims abstract description 12
- 235000020824 obesity Nutrition 0.000 claims abstract description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- OAWLZLONZCDJSJ-UHFFFAOYSA-N 2,2,17,17-tetramethyloctadecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCCCCCC(C)(C)C(O)=O OAWLZLONZCDJSJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001767 cationic compounds Chemical class 0.000 claims description 3
- ILHOYOUAJXQOAB-UHFFFAOYSA-N diethyl 4,4,13,13-tetramethylhexadeca-2,5,11,14-tetraenedioate Chemical compound CCOC(=O)C=CC(C)(C)C=CCCCCC=CC(C)(C)C=CC(=O)OCC ILHOYOUAJXQOAB-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 150000002892 organic cations Chemical class 0.000 claims description 3
- HSRNAICGDXHMSH-UHFFFAOYSA-N 4,4,11,11-tetramethyltetradecanedioic acid Chemical compound OC(=O)CCC(C)(C)CCCCCCC(C)(C)CCC(O)=O HSRNAICGDXHMSH-UHFFFAOYSA-N 0.000 claims description 2
- MKZKFKFOTOSWSD-UHFFFAOYSA-N 4,4,13,13-tetramethylhexadecanedioic acid Chemical compound OC(=O)CCC(C)(C)CCCCCCCCC(C)(C)CCC(O)=O MKZKFKFOTOSWSD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000037149 energy metabolism Effects 0.000 abstract description 3
- 208000002705 Glucose Intolerance Diseases 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract description 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- -1 sulpho Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- SDENLXLNLFKRAR-UHFFFAOYSA-N 1,14-dibromotetradecane Chemical compound BrCCCCCCCCCCCCCCBr SDENLXLNLFKRAR-UHFFFAOYSA-N 0.000 description 3
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- UEWNEQVNIYYFFF-UHFFFAOYSA-N triphenylphosphanium;dibromide Chemical compound [Br-].[Br-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 UEWNEQVNIYYFFF-UHFFFAOYSA-N 0.000 description 3
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 2
- WAZHJKKFQRONHO-UHFFFAOYSA-N 2,2,13,13-tetramethyltetradecanedioic acid Chemical compound OC(=O)C(C)(C)CCCCCCCCCCC(C)(C)C(O)=O WAZHJKKFQRONHO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 206010024626 Lipoprotein deficiency Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000020169 heat generation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical class OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- ZJJATABWMGVVRZ-UHFFFAOYSA-N 1,12-dibromododecane Chemical compound BrCCCCCCCCCCCCBr ZJJATABWMGVVRZ-UHFFFAOYSA-N 0.000 description 1
- DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 description 1
- BXXWFOGWXLJPPA-UHFFFAOYSA-N 2,3-dibromobutane Chemical compound CC(Br)C(C)Br BXXWFOGWXLJPPA-UHFFFAOYSA-N 0.000 description 1
- JJMOMMLADQPZNY-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanal Chemical compound OCC(C)(C)C=O JJMOMMLADQPZNY-UHFFFAOYSA-N 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- UHVWFURTTQVDEO-UHFFFAOYSA-N 4,4,15,15-tetramethyloctadecanedioic acid Chemical compound OC(=O)CCC(C)(C)CCCCCCCCCCC(C)(C)CCC(O)=O UHVWFURTTQVDEO-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- CWEBCFKHQPVXCF-UHFFFAOYSA-N C=CCCCCCCCCCCC=C.CC(C(=O)O)(CCCCCCCCCCCCCCC(C(=O)O)(C)C)C Chemical compound C=CCCCCCCCCCCC=C.CC(C(=O)O)(CCCCCCCCCCCCCCC(C(=O)O)(C)C)C CWEBCFKHQPVXCF-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001022645 Chondria <beetle> Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- 235000019787 caloric expenditure Nutrition 0.000 description 1
- 208000015669 capillary disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- QXYVMGNNVKUOKQ-AATRIKPKSA-N ethyl (e)-5-hydroxy-4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)\C=C\C(C)(C)CO QXYVMGNNVKUOKQ-AATRIKPKSA-N 0.000 description 1
- ZEXBDMFTZCHJOT-UHFFFAOYSA-N ethyl 2-bromoacetate 4,4,11,11-tetramethyltetradecanedioic acid Chemical compound BrCC(=O)OCC.CC(CCC(=O)O)(CCCCCCC(CCC(=O)O)(C)C)C ZEXBDMFTZCHJOT-UHFFFAOYSA-N 0.000 description 1
- NUIHHERNDWBSCX-UHFFFAOYSA-N ethyl 2-formyl-4-methylpent-2-enoate Chemical compound CCOC(=O)C(C=O)=CC(C)C NUIHHERNDWBSCX-UHFFFAOYSA-N 0.000 description 1
- HKOLTPVNONNDDR-UHFFFAOYSA-N ethyl 4,4-dimethyl-5-oxopent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C=O HKOLTPVNONNDDR-UHFFFAOYSA-N 0.000 description 1
- AGMKVZDPATUSMS-UHFFFAOYSA-N ethyl pent-2-enoate Chemical compound CCOC(=O)C=CCC AGMKVZDPATUSMS-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000001145 hydrido group Chemical class *[H] 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Natural products OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/602—Dicarboxylic acid esters having at least two carbon-to-carbon double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL119971 | 1997-01-07 | ||
| IL11997197A IL119971A (en) | 1997-01-07 | 1997-01-07 | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| PCT/IL1997/000427 WO1998030530A1 (en) | 1997-01-07 | 1997-12-25 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260665A Division JP5479857B2 (ja) | 1997-01-07 | 2009-11-16 | カルボン酸及びその誘導体及びそれらを含む薬剤組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001507713A true JP2001507713A (ja) | 2001-06-12 |
| JP2001507713A5 JP2001507713A5 (OSRAM) | 2005-08-11 |
Family
ID=11069666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53069798A Withdrawn JP2001507713A (ja) | 1997-01-07 | 1997-12-25 | カルボン酸及びその誘導体及びそれらを含む薬剤組成物 |
| JP2009260665A Expired - Fee Related JP5479857B2 (ja) | 1997-01-07 | 2009-11-16 | カルボン酸及びその誘導体及びそれらを含む薬剤組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009260665A Expired - Fee Related JP5479857B2 (ja) | 1997-01-07 | 2009-11-16 | カルボン酸及びその誘導体及びそれらを含む薬剤組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6284903B1 (OSRAM) |
| EP (2) | EP2112134B1 (OSRAM) |
| JP (2) | JP2001507713A (OSRAM) |
| KR (2) | KR100806927B1 (OSRAM) |
| AT (1) | ATE431816T1 (OSRAM) |
| AU (1) | AU742945B2 (OSRAM) |
| CA (1) | CA2277075C (OSRAM) |
| DE (1) | DE69739415D1 (OSRAM) |
| IL (1) | IL119971A (OSRAM) |
| WO (1) | WO1998030530A1 (OSRAM) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010519290A (ja) * | 2007-02-26 | 2010-06-03 | シンドロメクス リミテッド | 心血管系障害の治療のための併用療法、組成物及び方法 |
| JP2019507150A (ja) * | 2016-02-25 | 2019-03-14 | 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | 脂肪酸化合物、その製造方法及びその用途 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6814962B1 (en) * | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
| IL119971A (en) * | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| JP2002541129A (ja) | 1999-04-01 | 2002-12-03 | エスペリオン セラピューティクス インコーポレイテッド | エーテル化合物、組成物、およびそれらの使用 |
| CN1479721A (zh) | 2000-10-11 | 2004-03-03 | ͨ��ҽ�ƹ�˾ | 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物 |
| AU2002213136B2 (en) | 2000-10-11 | 2007-01-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US6703422B2 (en) | 2000-10-11 | 2004-03-09 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| US6713507B2 (en) | 2000-10-11 | 2004-03-30 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| WO2004067489A2 (en) | 2003-01-23 | 2004-08-12 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
| EP1701931B1 (en) | 2003-12-24 | 2018-10-10 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| WO2005062718A2 (en) * | 2003-12-30 | 2005-07-14 | Syndromex Ltd. | Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid |
| CA2617213C (en) | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| KR101444489B1 (ko) | 2007-02-01 | 2014-09-24 | 리스버로직스 코퍼레이션 | 심혈관 질환을 예방 및 치료하기 위한 화합물 |
| CA2688111A1 (en) | 2007-05-23 | 2008-12-04 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal |
| WO2009158404A1 (en) | 2008-06-26 | 2009-12-30 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| KR101803259B1 (ko) | 2009-03-18 | 2017-11-30 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| CN107252429B (zh) | 2009-04-22 | 2023-06-16 | 雷斯韦洛吉克斯公司 | 新抗炎剂 |
| EP3358008A1 (en) | 2009-09-03 | 2018-08-08 | Pfizer Vaccines LLC | Pcsk9 vaccine |
| BR112013008675A2 (pt) | 2010-09-20 | 2016-06-21 | Kareus Therapeutics Sa | métodos e composições para o tratamento de diabetes e dislipidemia |
| EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
| DK2773354T3 (da) | 2011-11-01 | 2019-08-05 | Resverlogix Corp | Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner |
| US10479752B2 (en) * | 2011-12-08 | 2019-11-19 | Syndromex Ltd. | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
| KR102662814B1 (ko) | 2015-03-13 | 2024-05-03 | 리스버로직스 코퍼레이션 | 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법 |
| MA42616A (fr) | 2015-03-13 | 2021-05-19 | Esperion Therapeutics Inc | Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| EP3463330B1 (en) * | 2016-06-02 | 2022-05-04 | Syndromex Ltd. | Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates |
| US10512624B2 (en) | 2016-11-30 | 2019-12-24 | Syndromex Ltd. | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 |
| CA3144372A1 (en) | 2019-06-21 | 2020-12-24 | Esperion Therapeutics, Inc. | Salt forms of bempedoic acid and methods for using the same |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1280244A (en) * | 1969-09-02 | 1972-07-05 | Parke Davis & Co | Serum triglyceride-lowering compositions |
| US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| JPS58131934A (ja) * | 1981-12-15 | 1983-08-06 | イッサム・リサーチ・デベロップメント・コンパニー・オブ・ザ・ヘベリュー・ユニバーシティー・オブ・エルサレム | 直鎖α，ω―ジカルボン酸誘導体 |
| JPS61171417A (ja) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | 抗糖尿病剤 |
| WO1996030328A1 (en) * | 1995-03-24 | 1996-10-03 | Warner-Lambert Company | Terminal carboxy or tetrazole groups containing dialkyl ethers |
| JP2003001549A (ja) * | 2001-06-26 | 2003-01-08 | Howa Mach Ltd | 光電式刃具折れ検知装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268082A (en) | 1969-08-08 | 1972-03-22 | Orsymonde | Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes |
| FR2288516A2 (fr) | 1974-10-21 | 1976-05-21 | Orsymonde | Nouveaux bis-(carboxyalcoylene-thio)-1,10 decanes et leurs derives |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| US4634975A (en) * | 1984-09-17 | 1987-01-06 | Progressive Dynamics, Inc. | Method and apparatus for producing electromagnetic surveillance fields |
| DE3512536A1 (de) * | 1985-04-06 | 1986-10-16 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3634356A1 (de) * | 1986-10-08 | 1988-04-21 | Epis Sa | Arzneimittel enthaltend alpha-halogenierte dicarbonsaeuren |
| DE4224670A1 (de) * | 1992-07-25 | 1994-01-27 | Boehringer Mannheim Gmbh | Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker |
| IL119971A (en) * | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
-
1997
- 1997-01-07 IL IL11997197A patent/IL119971A/xx not_active IP Right Cessation
- 1997-12-25 WO PCT/IL1997/000427 patent/WO1998030530A1/en not_active Ceased
- 1997-12-25 US US09/331,895 patent/US6284903B1/en not_active Expired - Lifetime
- 1997-12-25 JP JP53069798A patent/JP2001507713A/ja not_active Withdrawn
- 1997-12-25 EP EP09160514.7A patent/EP2112134B1/en not_active Expired - Lifetime
- 1997-12-25 DE DE69739415T patent/DE69739415D1/de not_active Expired - Lifetime
- 1997-12-25 AU AU79947/98A patent/AU742945B2/en not_active Ceased
- 1997-12-25 KR KR1020077003601A patent/KR100806927B1/ko not_active Expired - Fee Related
- 1997-12-25 KR KR1019997006147A patent/KR100806928B1/ko not_active Expired - Fee Related
- 1997-12-25 CA CA2277075A patent/CA2277075C/en not_active Expired - Fee Related
- 1997-12-25 AT AT97949080T patent/ATE431816T1/de not_active IP Right Cessation
- 1997-12-25 EP EP97949080A patent/EP0988274B1/en not_active Expired - Lifetime
-
2001
- 2001-06-18 US US09/881,812 patent/US6800772B2/en not_active Expired - Lifetime
-
2003
- 2003-10-08 US US10/680,429 patent/US20040132818A1/en not_active Abandoned
-
2009
- 2009-11-16 JP JP2009260665A patent/JP5479857B2/ja not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1280244A (en) * | 1969-09-02 | 1972-07-05 | Parke Davis & Co | Serum triglyceride-lowering compositions |
| US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
| US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| JPS58131934A (ja) * | 1981-12-15 | 1983-08-06 | イッサム・リサーチ・デベロップメント・コンパニー・オブ・ザ・ヘベリュー・ユニバーシティー・オブ・エルサレム | 直鎖α，ω―ジカルボン酸誘導体 |
| JPS61171417A (ja) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | 抗糖尿病剤 |
| WO1996030328A1 (en) * | 1995-03-24 | 1996-10-03 | Warner-Lambert Company | Terminal carboxy or tetrazole groups containing dialkyl ethers |
| JP2003001549A (ja) * | 2001-06-26 | 2003-01-08 | Howa Mach Ltd | 光電式刃具折れ検知装置 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010519290A (ja) * | 2007-02-26 | 2010-06-03 | シンドロメクス リミテッド | 心血管系障害の治療のための併用療法、組成物及び方法 |
| JP2019507150A (ja) * | 2016-02-25 | 2019-03-14 | 中国科学院上海薬物研究所Ｓｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ | 脂肪酸化合物、その製造方法及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000069934A (ko) | 2000-11-25 |
| AU742945B2 (en) | 2002-01-17 |
| EP0988274B1 (en) | 2009-05-20 |
| IL119971A0 (en) | 1997-04-15 |
| EP2112134B1 (en) | 2013-10-30 |
| EP0988274A4 (en) | 2000-10-18 |
| KR20070026888A (ko) | 2007-03-08 |
| KR100806928B1 (ko) | 2008-02-22 |
| AU7994798A (en) | 1998-08-03 |
| IL119971A (en) | 2003-02-12 |
| US20020049345A1 (en) | 2002-04-25 |
| JP5479857B2 (ja) | 2014-04-23 |
| US6284903B1 (en) | 2001-09-04 |
| ATE431816T1 (de) | 2009-06-15 |
| US20040132818A1 (en) | 2004-07-08 |
| CA2277075C (en) | 2010-06-22 |
| KR100806927B1 (ko) | 2008-02-22 |
| WO1998030530A1 (en) | 1998-07-16 |
| EP0988274A1 (en) | 2000-03-29 |
| US6800772B2 (en) | 2004-10-05 |
| DE69739415D1 (de) | 2009-07-02 |
| EP2112134A1 (en) | 2009-10-28 |
| JP2010077141A (ja) | 2010-04-08 |
| CA2277075A1 (en) | 1998-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001507713A (ja) | カルボン酸及びその誘導体及びそれらを含む薬剤組成物 | |
| EP0081930B1 (en) | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
| IL228630A (en) | Compounds for the treatment of metabolic syndrome and intermediates for the synthesis of these compounds | |
| JPH0112727B2 (OSRAM) | ||
| JPH0432073B2 (OSRAM) | ||
| JP5903166B2 (ja) | ブチルフタリドの誘導体、並びにその製造法及び使用 | |
| JP2954989B2 (ja) | ビスフェノール誘導体での真性糖尿病処置法 | |
| CN110511201B (zh) | 一类3′-氨烷氧基-木犀草素衍生物及其制备方法和应用 | |
| AU780162B2 (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
| CN113121331B (zh) | 具有环丙基的苯氧芳酸类化合物及其药学上可接受的盐，以及它们的制备方法和应用 | |
| EP0518769B1 (fr) | Nouveaux dérivés de benzoate d'éthanolamine, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
| JPH02250831A (ja) | ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びそれを有効成分とする抗消化性潰瘍剤 | |
| JP3010502B2 (ja) | ピロールアルデヒド誘導体 | |
| CA1223877A (fr) | Carbostyriloximinopropanolamines utiles comme medicaments et procede pour leur preparation | |
| MXPA99006358A (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
| JPH0662584B2 (ja) | 新規ヒダントイン誘導体及び該化合物を含有する脂質低下剤 | |
| JPS6399048A (ja) | アリールスルホンアミド型の化合物 | |
| JPH0578242A (ja) | アルドースレダクターゼ阻害剤 | |
| JPS59206330A (ja) | ナフチルオキシアルキルカルボン酸誘導体 | |
| JPH07165581A (ja) | イミダゾリジントリオン誘導体を含有する脂質低下剤 | |
| DE2125113B2 (de) | Bis-(4-chlorphenoxy-essigsäure-(N-methyl-pyrrolidyl-2)-methylester und dessen Säureanlagerungssalze, Verfahren zu seiner Herstellung sowie diese enthaltende ArzneimitteL | |
| JPH03161460A (ja) | 膵機能改善用処置剤 | |
| CH629795A5 (fr) | Derive de l'acide phenoxy acetique, sa preparation et son emploi therapeutique. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041203 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041203 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050114 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090203 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091124 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100107 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110309 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110411 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110414 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111012 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111017 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111116 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111213 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120113 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120608 |